---
schema_version: "secwatch.filing_event.v1"
accession: "0001839882-23-030323"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:25:29.828648+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tonix Q3 net loss $28M ($1.83/shr); cash drops to $6.9M; phase 3 fibromyalgia data due Dec 2023

## Summary
- Net product revenue of $4.0M in first quarter after acquiring Zembrace/Tosymra in June 2023.
- Cash and equivalents $6.9M at Sep 30, 2023 vs $120.2M at Dec 31, 2022.
- Public offerings in Aug and Sep 2023 raised net proceeds of $6.3M and $4.0M respectively.
- Topline Phase 3 RESILIENT trial (TNX-102 SL) for fibromyalgia expected late December 2023.
- Topline Phase 2 PREVENTION study (TNX-1900) for chronic migraine expected early December 2023.

## SEC filing metadata
- accession: 0001839882-23-030323
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/0001839882-23-030323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/tnxp-8k_110923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001839882-23-030323
- JSON: https://secwatch.observer/filing/0001839882-23-030323.json
- Plain text: https://secwatch.observer/filing/0001839882-23-030323.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000183988223030323/0001839882-23-030323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.